Orbital Therapeutics vs Regeneron
Side-by-side comparison of AI visibility scores, market position, and capabilities
Orbital Therapeutics is a next-gen RNA biotech that raised $270M Series A in 2023; advancing circular RNA and in vivo CAR-T programs for autoimmune disease; Bristol Myers Squibb announced a $1.5B acquisition in 2025;
About
Orbital Therapeutics is a clinical-stage biotechnology company founded in 2022 and headquartered in Cambridge, Massachusetts, with a mission to unlock the full potential of RNA medicines. The company operates at the frontier of RNA biology, advancing a platform that spans circular RNA, self-amplifying RNA, and in vivo CAR-T cell therapies — technologies designed to go beyond the mRNA approaches pioneered during the COVID-19 era. Orbital was co-founded by leading RNA scientists and backed by ARCH Venture Partners, a16z Bio + Health, Newpath Partners, the Abu Dhabi Growth Fund, and Redmile Group, among others.
Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.
About
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.